Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H6NO3.Mg |
| Molecular Weight | 280.5171 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=JQAACYUZYRBHGG-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Mg/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3271 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2111421 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date2012 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii. | 2002 |
|
| Expression and prognostic significance of lysozyme in male breast cancer. | 2002 |
|
| Continuous spectrometric assays for glutaminyl cyclase activity. | 2002 Apr 1 |
|
| Major outer membrane proteins and proteolytic processing of RgpA and Kgp of Porphyromonas gingivalis W50. | 2002 Apr 1 |
|
| Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase. | 2002 Apr 15 |
|
| CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. | 2002 Apr 2 |
|
| Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. | 2002 Aug 16 |
|
| Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid. | 2002 Jun 3 |
|
| Fluorometric assay using naphthylamide substrates for assessing novel venom peptidase activities. | 2002 Nov |
|
| Methacrylate derivatives incorporating pyroglutamic acid. | 2002 Nov-Dec |
|
| Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity. | 2002 Sep 3 |
|
| Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters. | 2002 Sep 6 |
|
| Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1. | 2003 Aug 19 |
|
| Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors. | 2003 Aug 7 |
|
| Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus. | 2003 Jul |
|
| Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues. | 2003 Jul 7 |
|
| 2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation. | 2003 Jun 7 |
|
| Origin of diastereoselection in the hydrosilylation of chiral N-acyliminium intermediates derived from pyroglutamic acid. | 2004 Apr 26 |
|
| Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
| Glutamine in commercial liquid nutritional products. | 2004 Aug 11 |
|
| Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
| Expression, purification, and characterization of avian Thy-1 from Lec1 mammalian and Tn5 insect cells. | 2004 Feb |
|
| Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
| Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. | 2004 Feb 24 |
|
| Integrative annotation of 21,037 human genes validated by full-length cDNA clones. | 2004 Jun |
|
| Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections. | 2004 Mar |
|
| Synthesis of (2S,3S)-3'-fluoroisoleucine. | 2004 Mar 7 |
|
| Skin secretion of the toad Bombina variegata contains multiple insulin-releasing peptides including bombesin and entirely novel insulinotropic structures. | 2004 Mar-Apr |
|
| Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein. | 2004 May 25 |
|
| Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. | 2004 May-Jun |
|
| Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). | 2004 Sep |
|
| Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes. | 2005 Apr |
|
| Emerging roles of apelin in biology and medicine. | 2005 Aug |
|
| Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. | 2005 Aug 2 |
|
| Nanoparticles on the basis of highly functionalized dextrans. | 2005 Aug 3 |
|
| Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid. | 2005 Aug 7 |
|
| Physiological and pathological aspects of GSH metabolism. | 2005 Feb |
|
| Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. | 2005 Jul |
|
| Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid). | 2005 Jul |
|
| Identification of novel bradykinin-potentiating peptides and C-type natriuretic peptide from Lachesis muta venom. | 2005 Jul |
|
| The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. | 2005 Jul 1 |
|
| CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis. | 2005 Jul 15 |
|
| Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame. | 2005 Jul 8 |
|
| Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoides. | 2005 May |
|
| Biomarker metabolites capturing the metabolite variance present in a rice plant developmental period. | 2005 May 31 |
|
| Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. | 2005 Nov 4 |
|
| Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme. | 2005 Sep |
|
| Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
|
| Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.). | 2005 Sep 25 |
|
| CFSUM1 and CFSUM2 in urine from patients with chronic fatigue syndrome are methodological artefacts. | 2006 Feb |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12CC08
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
||
|
WHO-ATC |
A12CC08
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MAGNESIUM PIDOLATE
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
DBSALT002689
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL397976
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
V5PC588N7G
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
14559042
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
100000089075
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
116240
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
4597
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
263-365-7
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
SUB03045MIG
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY | |||
|
62003-27-4
Created by
admin on Mon Mar 31 18:32:22 GMT 2025 , Edited by admin on Mon Mar 31 18:32:22 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
